Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!

Biomarkers or biosignature profiles have become accessible over time in population-based studies for Chagas disease. Thus, the identification of consistent and reliable indicators of the diagnosis and prognosis of patients with heart failure might facilitate the prioritization of therapeutic management to those with the highest chance of contracting this disease. The purpose of this paper is to review the recent state and the upcoming trends in biomarkers for human Chagas disease. As an emerging concept, we propose a classification of biomarkers based on plasmatic-, phenotype-, antigenic-, genetic-, and management-related candidates. The available data revisited here reveal the lessons learned thus far and the existing challenges that still lie ahead to enable biomarkers to be employed consistently in risk evaluation for this disease. There is a strong need for biomarker validation, particularly for biomarkers that are specific to the clinical forms of Chagas disease. The current failure to achieve the eradication of the transmission of this disease has produced determination to solve this validation issue. Finally, it would be strategic to develop a wide variety of biomarkers and to test them in both preclinical and clinical trials.

• Publication year

  2016

• Venue

  Frontiers in Immunology

• Publication date

  2016-08-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2016.00306PMID 27563302PMCID 4980390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers and mortality in severe Chagas cardiomyopathy.

  2015cited by this paper
• Aptamer-Based Detection of Disease Biomarkers in Mouse Models for Chagas Drug Discovery

  2015cited by this paper
• Immunity and immune modulation in Trypanosoma cruzi infection.

  2015cited by this paper
• Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion

  2015cited by this paper
• Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans

  2015cited by this paper
• Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

  2015cited by this paper
• Plasma Cytokine Expression Is Associated with Cardiac Morbidity in Chagas Disease

  2014cited by this paper
• Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi.

  2014cited by this paper
• MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in Chronic Chagas disease Cardiomyopathy.

  2014cited by this paper
• Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review

  2014cited by this paper
• Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment

  2014cited by this paper
• Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice

  2014influential reference
• Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review

  2013cited by this paper
• Genetic susceptibility to Chagas disease cardiomyopathy: involvement of several genes of the innate immunity and chemokine-dependent migration pathways

  2013cited by this paper
• Administration of granulocyte colony‐stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy

  2013cited by this paper
• Cell Death and Serum Markers of Collagen Metabolism during Cardiac Remodeling in Cavia porcellus Experimentally Infected with Trypanosoma cruzi

  2013cited by this paper
• Matrix Metalloproteinases 2 and 9 Are Differentially Expressed in Patients with Indeterminate and Cardiac Clinical Forms of Chagas Disease

  2013cited by this paper
• Predictive value of transforming growth factor-β1in Chagas disease: towards a biomarker surrogate of clinical outcome.

  2013cited by this paper
• The TGF‐β Pathway as an Emerging Target for Chagas Disease Therapy

  2012cited by this paper
• Deficient Regulatory T Cell Activity and Low Frequency of IL-17-Producing T Cells Correlate with the Extent of Cardiomyopathy in Human Chagas' Disease

  2012cited by this paper
• Oral Administration of GW788388, an Inhibitor of Transforming Growth Factor Beta Signaling, Prevents Heart Fibrosis in Chagas Disease

  2012cited by this paper
• Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease.

  2011cited by this paper
• Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease.

  2011cited by this paper
• Regulatory T Cells Phenotype in Different Clinical Forms of Chagas' Disease

  2011cited by this paper
• Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic.

  2010cited by this paper
• Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy.

  2010cited by this paper
• Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP.

  2010cited by this paper
• Gap junction reduction in cardiomyocytes following transforming growth factor-beta treatment and Trypanosoma cruzi infection.

  2009cited by this paper
• Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy.

  2008cited by this paper
• Clinical aspects of the Chagas' heart disease.

  2007cited by this paper
• Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients.

  2006cited by this paper
• Uptake of host cell transforming growth factor-beta by Trypanosoma cruzi amastigotes in cardiomyocytes: potential role in parasite cycle completion.

  2005cited by this paper
• TGF-β1 and angiotensin networking in cardiac remodeling

  2004cited by this paper
• Activation of transforming growth factor β by Trypanosoma cruzi

  2004cited by this paper
• TGF-beta1 and angiotensin networking in cardiac remodeling.

  2004cited by this paper
• Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

  2002cited by this paper
• Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease.

  2002cited by this paper
• Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy.

  2002cited by this paper
• α4 Integrins and Sialyl Lewis x Modulation in Chronic Chagas Disease: Further Evidence of Persistent Immune Activation

  2001cited by this paper
• Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease

  1995cited by this paper
• Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.

  1993cited by this paper
• Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta)

  1991cited by this paper
• The pattern of myocardial fibrosis in chronic Chagas' heart disease.

  1991cited by this paper
• [CLINICAL ASPECTS OF CHAGAS' HEART DISEASE].

  1963influential reference

• Biomarkers for the diagnosis, treatment follow‐up, and prediction of cardiac complications in Chagas disease in chronic phase: Recent advances

  2023cites this paper
• Parasite DNA and Markers of Decreased Immune Activation Associate Prospectively with Cardiac Functional Decline over 10 Years among Trypanosoma cruzi Seropositive Individuals in Brazil

  2023cites this paper
• Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure

  2022cites this paper
• Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.

  2021cites this paper
• Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy

  2021cites this paper
• Nano-Medicines a Hope for Chagas Disease!

  2021cites this paper
• Fibronectin degradation as biomarker for Trypanosoma cruzi infection and treatment monitoring in mice

  2021cites this paper
• Biomarkers assessment in patients with Chagas disease and systemic arterial hypertension

  2020cites this paper
• Why hasn’t there been more progress in new Chagas disease drug discovery?

  2020cites this paper
• Review of pharmacological options for the treatment of Chagas disease

  2020cites this paper
• Trypanosoma cruzi immunoproteome: Calpain-like CAP5.5 differentially detected throughout distinct stages of human Chagas disease cardiomyopathy.

  2019cites this paper
• Trypanosoma cruzi Trypomastigote Glycosylphosphatidylinositol-Anchored Mucins And A Synthetic Alpha-Gal-Containing Neoglycoprotein As Potential Biomarkers And Vaccines For Chagas Disease

  2019cites this paper
• Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

  2019cites this paper
• A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection

  2019cites this paper
• Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole

  2018cites this paper
• Biosensors to Diagnose Chagas Disease: A Brief Review

  2017cites this paper
• A multi-parametric analysis of Trypanosoma cruzi infection: common pathophysiologic patterns beyond extreme heterogeneity of host responses

  2017cites this paper
• Biomarkers for Chagas Disease

  2015influential citation